Who is sponsoring NCT00680628?

NCT00680628 is sponsored by Wake Forest University Health Sciences.

What condition does NCT00680628 study?

NCT00680628 studies Pulmonary Embolism.

What drugs are being tested in NCT00680628?

Interventions: Tenecteplase + Enoxaparin, 0.9% Saline + Enoxaparin.

What is the status of NCT00680628?

NCT00680628 is currently TERMINATED.

Last reviewed 2022-10-07 · How we verify

Randomized Trial of Tenecteplase to Treat Severe Submassive Pulmonary Embolism

NCT00680628 Phase 3 TERMINATED Results posted

The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.

Details

Lead sponsor	Wake Forest University Health Sciences
Phase	Phase 3
Status	TERMINATED
Enrolment	83
Start date	2008-05
Completion	2012-10

Conditions

Pulmonary Embolism

Interventions

Tenecteplase + Enoxaparin
0.9% Saline + Enoxaparin

Primary outcomes

Number of Patients With Cardiogenic Shock or Respiratory Failure From Pulmonary Embolism and Number of Patietnts With Major Hemorrhage — 1,2,3,4, and 5 days
Number With Functional Cardiopulmonary Limitations Assessed With a Composite Measurement (Six Minute Walk Distance, Right Ventricular Function and Quality of Life Score on the SF-36) — 90 days
Number With Recurrent Venous Thromboembolism and/or Severe Post-phlebitic Syndrome — 90 days

Countries

United States